WuXi Biologics (Cayman) company profile

2269 · HKEX · HKD

$46.74Change from previous close: 0.00%

Close · November 16, 2026

Company profile

WuXi Biologics (Cayman) has 14,705 employees and is headquartered in Wuxi, China.

The company is best known for platforms such as WuXiBody, SDArBodY, WuXiUP and WuXiHigh, which it applies across biologics work. Its activities run from early discovery and the preparation of investigational new drug filings through process development and commercial-scale production, and also include vaccine contract manufacturing, clinical and manufacturing services, and the development, production and distribution of biotechnological products. Operations are organised in two segments, Biologics and XDC, and the company serves customers in China, North America, Europe, Singapore, Japan, South Korea, Australia and Brazil.

In the fiscal year ended December 2025, revenue reached CNY 21.8 billion, up 16.7% from the previous year, and net profit stood at CNY 4.9 billion. The company had 14,705 employees at the end of the period, and it is headquartered in Wuxi, China, where it was incorporated in 2014.

Company facts

Industry
Biotechnology
Headquarters
No. 108, Meiliang Road, Wuxi
Employees
14,705
Chief executive
Zhisheng Chen
Founded
2014
Fiscal year
January - December
Listing
2269 · HKEX
Indices
Hang Seng
Currency
HKD
ISIN
KYG970081173

WuXi Biologics (Cayman) and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
WuXi Biologics (Cayman)2269Hong Kong SAR China$24.52B14,70532.4%35.1
Innovent Biologics1801Hong Kong SAR China$18.84B8,7547.4%111.5
Celltrion068270South Korea$36.68B2,95631.6%26.4
Sichuan Kelun-Biotech Biopharmaceutical6990Hong Kong SAR China$13.65B2,300-0.2%—
Sino Biopharmaceutical1177Hong Kong SAR China$12.49B22,83828.2%36.7
Samsung Biologics207940South Korea$49.13B5,32645.5%33.4

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare WuXi Biologics (Cayman) with its competitors